Professor John Newell-Price

MA, PhD, FRCP

Department of Oncology and Metabolism

Chair of Endocrinology

Honorary Consultant Physician

John Newell-Price
j.newellprice@sheffield.ac.uk
+44 114 215 9018
+44 114 215 9024 (admin assistance contact)

Full contact details

Professor John Newell-Price
Department of Oncology and Metabolism
EU07, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

John Newell-Price trained in medicine at the University of Cambridge and then the Royal London Hospital. He did his specialist training in endocrinology at St. Bartholomew's Hospital, London, where he was an MRC Training Fellow from 1995-1998. He was appointed Senior Lecturer and Honorary Consultant Physician at the University of Sheffield in 2000.

The focus of both his clinical and basic research is glucocorticoids. His group has identified important aspects of epigenetic regulation of proopiomelanocortin, the key regulator of the hypothalamic-pituitary-adrenal axis, and now is using this information to design strategies to modify over-expression in conditions of excess hormone secretion, such as Cushing's disease.

The clinical research programme has been investigating means of inhibiting excess ACTH in man and improving cortisol replacement in adrenally insufficient patients. This has led to the testing of Chronocort, a new and modified-release form of hydrocortisone, in Phase I studies, which has proven to replicate the normal circadian rhythm of cortisol.

Other work focuses on the diagnostic and management strategies for patients with Cushing's syndrome, and those also for patients with neuroendocrine tumours.

In the Healthcare Trust, John chairs the Pituitary and Neuroendocrine Tumour Multidisciplinary Teams.

Publications

Journal articles

Chapters

  • Newell-Price JDC (2017) Cushing Disease, The Pituitary (pp. 515-571). Elsevier RIS download Bibtex download
  • Beckers A, Ben-Shlomo A, Bichet DG, Binart N, Bonert VS, Bronstein MD, Buchfelder M, Carmichael JD, Chanson P, Daly AF , Donoho DA et al (2017) List of Contributors, The Pituitary (pp. ix-ix). Elsevier RIS download Bibtex download
  • Newell-Price JDC (2017) Cushing Disease, The Pituitary: Fourth Edition (pp. 515-571). RIS download Bibtex download

Conference proceedings papers

  • Arshad MF, Kaluarachchi V, Iqbal A, Munir A & Newell-Price JDC (2020) SUN-299 Flash Glucose Sensor Monitoring for Patients with Endogenous Hyperinsulinaemic Hypoglycaemia. Journal of the Endocrine Society, Vol. 4(Supplement_1) RIS download Bibtex download
  • Ross RJ, Harrison RF, Debono M, Whitaker MJ, Keevil BG & Newell-Price J (2017) SERUM CORTISOL AND SALIVARY CORTISONE AND FREQUENCY OF SAMPLING TO ESTIMATE CORTISOL EXPOSURE. HORMONE RESEARCH IN PAEDIATRICS, Vol. 88 (pp 53-54) RIS download Bibtex download
  • Robins JM, Ayuk J, Trainer PJ & Newell-Price J (2014) Stereotactic gamma knife radiosurgery as an effective treatment for acromegaly. Journal of the American College of Surgeons, Vol. 219(4) (pp e24-e24) RIS download Bibtex download
  • Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M, Tomassetti P, Weber M, Fogelman DR, Ramage J , Poon D et al (2013) A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download
  • Walsh J, Newell-Price J, Debono M & Eastell R (2012) HIGH CIRCULATING SEROTONIN IN CARCINOID SYNDROME IS NOT ASSOCIATED WITH ALTERATIONS IN BONE TURNOVER OR BONE DENSITY. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S536-S537) RIS download Bibtex download
  • Walsh JS, Newell-Price JD, Debono M & Eastell R (2012) High circulating serotonin in carcinoid syndrome is not associated with alterations in bone turnover or bone density. BONE, Vol. 50 (pp S53-S53) RIS download Bibtex download
  • Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A & Biller BMK (2010) Baseline Characteristics and Urine Free Cortisol (UFC) Variability of 162 Patients Enrolled in a Randomized, Double-Blind Phase III Study Assessing the Efficacy and Safety of Pasireotide (SOM230) in Patients with Cushing's Disease.. ENDOCRINE REVIEWS, Vol. 31(3) RIS download Bibtex download
Grants
  • Society for Endocrinology, £120,000, 2005-2008. RNA interference as therapy for models of Cushing's disease and acromegaly.
  • Sheffield Hospitals' Charitable Trust, £24,995, 2006-2008. RNA interference as therapy for models of Cushing's disease and acromegaly.
  • European Union, 450,000 Euros (Joint partner). European Register on Cushing's Syndrome, in Framework of Public Health Programme. 2007-2010.
Professional activities

National Committee Membership

  • Society for Endocrinology Clinical Subcommittee, 1997-2000.
  • Chair of the UK Medical Committee, Pituitary Foundation, UK, 2007.
  • UK and Ireland Neuroendocrine Tumour Society, Executive Officer, 2007.
  • UK Acromegaly Database Steering Committee, 2005-to date.

Editorship

  • Associate Editor of Clinical Endocrinology 2001-to date.
  • Editorial Board, Clinical Endocrinology, 2001-to date.
  • Editorial Board, Journal of Clinical Endocrinology and Metabolism, 2008-2010.

Advisory Boards

  • NICE Appraisal of Pituitary Disease, 2004-2005.

National and International Guidelines

  • Task Force Member (one of six) for the American Endocrine Society's Guidelines on the Diagnosis of Cushing's Syndrome.